Substance / Medication

Aducanumab

Overview

Active Ingredient
aducanumab
RxNorm CUI
2557217

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:
Aducanumab for the treatment of Alzheimer's disease: a systematic review.
Rahman Afroza, Hossen Md Anwar, Chowdhury Mirza Farhana Iqbal et al. · Psychogeriatrics · 2023
PMID: 36775284Meta-AnalysisFull text (PMC)
Results from the long-term extension of PRIME: A randomized Phase 1b trial of aducanumab.
Chen Tianle, O'Gorman John, Castrillo-Viguera Carmen et al. · Alzheimers Dement · 2024
PMID: 38567735RCTFull text (PMC)
CSF biomarker concordance with amyloid PET in Phase 3 studies of aducanumab.
Nisenbaum Laura, Martone Robert, Chen Tianle et al. · Alzheimers Dement · 2023
PMID: 36795603RCT
Investigating Partially Discordant Results in Phase 3 Studies of Aducanumab.
Mallinckrodt C, Tian Y, Aisen P S et al. · J Prev Alzheimers Dis · 2023
PMID: 36946443RCT

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Aducanumab (substance)
SNOMED CT
1162583000
UMLS CUI
C4043101
RxNorm CUI
2557217

Clinical Data

This intervention maps to 1 entities in the Ltrl knowledge graph.

1
Conditions
0
Biomarkers
0
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.